Lung Diseases
Support for named pulmonary diagnoses: idiopathic pulmonary fibrosis, bronchiectasis, post-COVID pulmonary sequelae, and refractory asthma, always alongside your pulmonologist.
Personalized review, grounded in your health history.
Understanding This Condition
Lung disease is a broad category, not a single diagnosis. Asthma, pulmonary fibrosis, bronchiectasis, sarcoidosis, chronic infections, and other conditions affect the lungs in different ways and require different testing and treatment. If you have new or worsening shortness of breath, chest pain, coughing up blood, a fever with breathlessness, or an oxygen reading that has dropped, call 911 or go to the nearest emergency department rather than booking a consultation.
Because the causes and risks vary, any discussion must begin with a confirmed diagnosis and current pulmonary care. The conditions this group currently covers are idiopathic pulmonary fibrosis, bronchiectasis, post-COVID pulmonary sequelae, and refractory asthma. Cellular and regenerative approaches are being studied in selected conditions, but they are not established general treatment for lung disease. The FDA warns that regenerative products promoted for pulmonary conditions may be unapproved.
Our consultation reviews your diagnosis, current stability, respiratory medication, oxygen needs, recent testing, and goals. A licensed provider explains the limits of the evidence and decides whether any supportive assessment is appropriate. Many lung conditions will not be eligible.
If your diagnosis is chronic obstructive pulmonary disease, start on our COPD page. If your symptoms began after a COVID infection, start on Long COVID Supportive Care.
Potential Benefits
The consultation may help you:
- A structured review of your specific pulmonary diagnosis, recent testing, and current respiratory care
- A plain account of why no regenerative product is approved as a general treatment for lung disease
- Screening for factors that affect eligibility, including stability, oxygen needs, and active infection
- Questions to discuss with your pulmonologist
- A practical next step if a licensed provider recommends further assessment
Who May Benefit
An assessment may make sense for people including:
- Adults with a confirmed chronic lung diagnosis who remain under pulmonary care
- People whose condition is clinically stable enough for a nonurgent consultation
- Individuals seeking an evidence-aware discussion of emerging research
- People able to share recent pulmonary testing and medication information
- Adults who understand that established respiratory care must continue
Therapies a Provider May Consider
Every option is reviewed individually after your history, current care, and goals are understood.
Exosome Therapy
Exosome therapy works with the signaling vesicles your cells already use to communicate. Studied for recovery, skin quality and healthy aging, and always planned by a licensed provider.
Learn MoreNAD+ Therapy
NAD+ is the coenzyme your cells use to turn food into energy, and levels fall with age. A leading choice for support with energy, mental clarity and recovery.
Learn MoreMUSE Cell Therapy
A stress enduring cell type able to develop into many tissue types. Explored for healthy aging, recovery and whole body cellular wellness, always guided by clinical review.
Learn MoreStem Cell Therapy
The body's own building and repair cells, and the foundation of regenerative medicine. Explored for recovery, mobility and healthy aging through physician guided planning.
Learn MoreWhat the Research Looks At
Lung diseases differ substantially in cause, severity, and established treatment. Regenerative products are not approved as a general treatment for pulmonary conditions. The references below provide lung-health context, the FDA warning, and registered-study information.
Start With an Assessment
Every visit begins with a consultation and a medical screening. A licensed provider decides what, if anything, is appropriate for you.